We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+19.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
+$244M
Cap. Flow
+$74.7M
Cap. Flow %
4.68%
Top 10 Hldgs %
27.52%
Holding
150
New
14
Increased
55
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$36M
2
AMRN
Amarin Corp
AMRN
+$13.9M
3
TSRO
TESARO, Inc.
TSRO
+$13.7M
4
DHR icon
Danaher
DHR
+$12.8M
5
PTHN
Patheon N.V.
PTHN
+$11M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
2
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.8M
4
MD icon
Pediatrix Medical
MD
+$9.92M
5
XNPT
XENOPORT, INC.
XNPT
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
2 Financials 3.67%
3 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$16.6B
$20.8M 1.3%
410,000
+500
+0.1% +$24.9K
PEN icon
27
Penumbra
PEN
$12.8B
$20.3M 1.27%
266,500
+24,000
+10% +$1.66M
PRTA icon
28
Prothena Corp
PRTA
$450M
$18.5M 1.16%
308,000
– –
BIIB icon
29
Biogen
BIIB
$30.7B
$18.2M 1.14%
58,000
+350
+0.6% +$104K
PCRX icon
30
Pacira BioSciences
PCRX
$997M
$17.2M 1.08%
504,000
+31,500
+7% +$1.23M
AMRN
31
Amarin Corp
AMRN
$303M
$15.8M 0.99%
+247,787
New +$13.9M
AMGN icon
32
Amgen
AMGN
$222B
$15.7M 0.98%
94,000
– –
WMGI
33
DELISTED
Wright Medical Group Inc
WMGI
$15M 0.94%
613,000
+65,100
+12% +$1.5M
INCY icon
34
Incyte
INCY
$24.4B
$14.8M 0.93%
156,500
+1,500
+1% +$126K
PRAH
35
DELISTED
PRA Health Sciences, Inc.
PRAH
$14.3M 0.9%
253,000
– –
MCK icon
36
McKesson
MCK
$101B
$13.7M 0.86%
82,000
+4,100
+5% +$764K
LKFT
37
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$13.6M 0.85%
210,000
– –
BMY icon
38
Bristol-Myers Squibb
BMY
$132B
$13.5M 0.85%
250,000
+53,500
+27% +$3.44M
JAZZ icon
39
Jazz Pharmaceuticals
JAZZ
$16.7B
$13M 0.81%
107,000
+5,000
+5% +$674K
WBA
40
DELISTED
Walgreens Boots Alliance
WBA
$13M 0.81%
161,000
+600
+0.4% +$48.9K
DHR icon
41
Danaher
DHR
$144B
$12.5M 0.79%
+180,480
New +$12.8M
CHRS icon
42
Coherus Oncology
CHRS
$196M
$12.5M 0.78%
467,500
+67,500
+17% +$1.84M
EW icon
43
Edwards Lifesciences
EW
$51.7B
$12.4M 0.78%
309,750
+59,250
+24% +$2.23M
TXMD icon
44
TherapeuticsMD
TXMD
$24M
$12.3M 0.77%
36,000
+4,500
+14% +$1.64M
DERM
45
DELISTED
Dermira, Inc.
DERM
$12M 0.75%
355,000
+100
+0% +$3.22K
PTHN
46
DELISTED
Patheon N.V.
PTHN
$11.9M 0.74%
+400,000
New +$11M
TVTX icon
47
Travere Therapeutics
TVTX
$5.78B
$11.7M 0.73%
522,000
+600
+0.1% +$11.4K
BMRN icon
48
BioMarin Pharmaceuticals
BMRN
$12.4B
$11.6M 0.73%
125,000
+12,000
+11% +$1.13M
EHC icon
49
Encompass Health
EHC
$12.4B
$10.8M 0.67%
333,105
– –
ACHN
50
DELISTED
Achillion Pharmaceuticals
ACHN
$10.7M 0.67%
1,316,000
+3,500
+0.3% +$29.8K
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rock Springs Capital Management held 150 positions worth $1.6B, up 18% from $1.35B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $74.7M of net new capital in Q3 2016, opening 14 new positions and adding to 55 existing holdings. Its largest new stake was Merck: 615,700 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Pediatrix Medical, an estimated $9.92M trimmed.

  • Rock Springs Capital Management's largest Q3 2016 buy was Merck: 615,700 shares worth $36.7M.
  • Rock Springs Capital Management added most to TESARO, Inc. in Q3 2016, an estimated $13.7M increase.
  • Rock Springs Capital Management's biggest Q3 2016 reduction was Pediatrix Medical, cutting an estimated $9.92M.
  • Rock Springs Capital Management fully exited Teva Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.6B portfolio in Q3 2016.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q3 2016.
  • Rock Springs Capital Management's portfolio value rose 18% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.